Topline: Taxpayers spent $74.5 million to help develop the prostate cancer-fighting drug Xtandi, but its sky-high sticker ...

In this video, Tanya Dorff, MD discusses the current state of the pipeline for developing castration-resistant prostate cancer treatments.

A paper inadvertently published on the website of an ASCO conference revealed good results for mevrometostat in treating ...

The company, now based in North Beach, has lost more than $2 billion over 29 years. Its only approved drug, called roxadustat ...

A local scientist is using artificial intelligence to find new uses for existing drugs to hopefully save both lives and money ...

The 63-year-old musician revealed his stage 4 prostate cancer diagnosis in November 2022, saying his cancer was “asymptomatic ...

Mutations in the BRCA1 gene that are either inherited (germline) or acquired (somatic) might not be key to the initiation of prostate cancer, as previously thought, suggests the first study of its ...

Earlier this month, the Norwegian government launched the cancer strategy Joint Efforts Against Cancer, with five national ...

The findings could lead to the development of new drugs with fewer side effects, for use in applications such as strengthening the ... Alarming Rise in Rates of Advanced Prostate Cancer in ...

Combining an existing small-molecule protein therapy called tumor necrosis factor related apoptosis-inducing ligand (TRAIL) ...

Swiss pharma giant Novartis is taking legal action against the Australian cancer care provider as a dispute over how to fund ...

Researchers at Rice University and Vanderbilt University found that combining focused ultrasound (FUS) with TRAIL protein therapy significantly reduces prostate tumor size in lab models. The treatment ...